25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 25,322 shares of the company’s stock, valued at approximately $1,943,000.

Several other large investors have also modified their holdings of the stock. NewSquare Capital LLC grew its position in AstraZeneca by 149.3% in the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. Richardson Financial Services Inc. boosted its holdings in shares of AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares in the last quarter. FSA Wealth Management LLC increased its stake in shares of AstraZeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after acquiring an additional 376 shares during the period. VSM Wealth Advisory LLC purchased a new position in AstraZeneca during the second quarter worth about $33,000. Finally, Maseco LLP acquired a new stake in AstraZeneca in the second quarter valued at about $34,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ:AZN opened at $92.51 on Wednesday. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $94.01. The firm has a market cap of $286.92 billion, a price-to-earnings ratio of 30.73, a price-to-earnings-growth ratio of 1.72 and a beta of 0.31. The company’s 50-day moving average is $88.70 and its two-hundred day moving average is $80.80. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.08 earnings per share. Research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on AZN. Jefferies Financial Group assumed coverage on AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a report on Wednesday, December 3rd. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.